Dr. Wayne Holman, the CEO and Founder of Ridgeback Capital, is a licensed physician and graduate of New York University School of Medicine with an undergraduate degree in economics from Yale University. Additionally, he is the co-founder of Ridgeback Biotherapeutics and serves as Co-Chair of the Ridgeback-Merck Molnupiravir Joint Steering Committee. He also serves as a member of the NYU Langone Board of Trustees and the University of Miami Board of Trustees. With a track record spanning over two decades, Dr. Holman has contributed funding to over 100 public and private biopharma companies, supporting the research and development of transformative medicines to address unmet needs. Residing in Miami, he shares his home with his wife, four children, and three dogs.
Ridgeback Capital was founded in 2006 and is focused on healthcare investments. Ridgeback invests in private and public companies that are dedicated to the development of life saving and life changing therapies. Healthcare advances take many years to materialize and Dr. Wayne Holman believes that patient capital is vital for new technologies and companies to thrive.
More about the team.